CPhi Preview 2013: Jost Chemicals - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

CPhi Preview 2013: Jost Chemicals


Untitled Document

2013 CPhI Exhibitor Preview

Company: Jost Chemical Co.

Description: For almost 30 years, Jost Chemical Co. has manufactured high purity inorganic chemicals for use in API synthesis, as pH buffers, as process intermediates, and in cell culture media and protein synthesis. Jost’s FDA registered site operates under bulk pharmaceutical cGMP. Jost is a global supplier of high purity salts that meet USP/EP/BP/JP monographs, are BSE/TSE free, and Kosher and Halal certified. Our wide selection of 250 + products includes carbonates, nitrates, phosphates and sulfates. Jost also offers DMF and ASMF developments.

Website: www.jostchemical.com

Booth Number: Hall 5.1 Stand D40

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
30%
Breakthrough designations
10%
Protecting the supply chain
40%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here